Cts Corporation · NYSE:CTS
Cts — FY2025 Earnings Presentation
20 slides from Cts's earnings presentation, Feb 10, 2026
Slide 1: CTS Corporation 4th Quarter and Full-Year 2025 Earnings Call
CTS Corporation 4th Quarter and Full-Year 2025 Earnings Call February 10, 2026
Slide 2: Cautionary Statement Regarding Forward-Looking Statements
Cautionary Statement Regarding Forward-Looking Statements Readers are cautioned that the statements contained in this document regarding expectations of our performance or other matters that may affect our business, results of operations, or financial condition are, or may be deemed to be, “forward-
Slide 3: Q4 and Full-Year 2025 – Strong Growth in Diversified Markets and Operational Execution
Q4 and Full-Year 2025 – Strong Growth in Diversified Markets and Operational Execution Fourth Quarter 2 • Solid growth from diversified end markets $137M 39.1% $0.62 - Revenue +16% for Q4 2025 1 1 Revenue Adj. Gross Margin Adj. Diluted EPS - Revenue +16% for full year 2025 +9% +150 bps +23% - 59% of
Slide 4: End Markets Update: Medical and Aerospace & Defense
End Markets Update Revenue ($ Millions) • FY 2025 Sales up 21%; book to bill 1.07 • Q4 2025 Sales up 41% vs. Q4 2024 $85 Medical $68 $70 • Robust growth driven by therapeutic and minimally invasive applications • Multiple Q4 wins across all regions in medical 2023 FY 2024 FY 2025 FY ultrasound, ther
Slide 5: End Markets Update: Industrial and Transportation
End Markets Update Revenue ($ Millions) • FY 2025 Sales up 12%; book to bill 1.11 • Q4 Sales up 16% year-over-year Industrial $140 $129 $125 • Continued recovery from cyclical lows across OEM and distribution customers • Multiple Q4 wins across distribution, industrial 2023 FY 2024 FY 2025 FY printi
Slide 6: FY 2026 Guidance
FY 2026 Guidance Revenue Adjusted Diluted EPS 1 ($ Millions) $580 $2.45 $550 $2.30 $550 $541 $515 $2.22 $2.23 $2.12 2023 2024 2025 2026F 2023 2024 2025 2026F Key Outlook Assumptions - Continued progress on growth in diversified end-markets - Softness in commercial vehicle-related sales in 2026 - Lig
Slide 7: 4th Quarter and Full-Year 2025 Financial Results
4th Quarter and Full-Year 2025 Financial Results
Slide 8: Q4 2025 Financial Summary
Q4 2025 Financial Summary Results Highlights ($ Millions, except percentages and per share amounts) Revenue $143 $137 • Revenue up 9% vs. Q4 2024 $127 • Diversified end market revenues up 16% vs. Q4 2024 • SyQwest $6m revenue in Q4 Q4 2024 Q3 2025 Q4 2025 • Transportation revenues down 1% year-over-
Slide 9: Full-Year 2025 Financial Summary
Full-Year 2025 Financial Summary Results Highlights ($ Millions, except percentages and per share amounts) Revenue • Revenue up 5% year over year $515 $541 • Diversified end market revenues up 16% vs. 2024 • SyQwest added $22m in revenue FY 2024 FY 2025 • Transportation revenues down 7% Net Income $
Slide 10: Prioritizing strong cash flow generation
Prioritizing strong cash flow generation Operating Cash Flow Cash and Debt1 ($ Millions) ($ Millions) $98 $102 $300 Total Facility $89 $82 $58 Borrowed 2023 FY 2024 FY 2025 FY Cash Debt $86M $62M 2 FY 2025 Free Cash Flow Cash Returned to Shareholders FY 20253 $16M Strong Balance Sheet FY 2025 Capita
Slide 11: Q&A
Q&A cts
Slide 12: Appendix
Appendix cts
Slide 13: Non-GAAP Financial Measures
Non-GAAP Financial Measures From time to time, CTS may use non-GAAP financial measures in discussing CTS’ business. These measures are intended to supplement, not replace, CTS’ presentation of its financial results in accordance with U.S. GAAP. CTS believes that the non-GAAP financial measures prese
Slide 14: Regulation G Schedules: Adjusted Gross Margin
Regulation G Schedules Adjusted Gross Margin ($ Millions, except percentages) Three Months Three Months Ended Ended Twelve Months Ended December 31, September 30, December 31, 2025 2024 2025 2025 2024 2023 Gross margin $ 53.7 $ 46.9 $ 55.3 $ 208.0 $ 187.6 $ 190.9 Net sales $ 137.3 $ 126.5 $ 143.0 $
Slide 15: Regulation G Schedules: Adjusted Operating Earnings
Regulation G Schedules Adjusted Operating Earnings ($ Millions, except percentages) Three Months Ended Twelve Months Ended December 31, December 31, 2025 2024 2025 2024 2023 Operating earnings $ 22.7 $ 18.0 $ 82.6 $ 71.2 $ 75.1 Net sales $ 137.3 $ 126.5 $ 541.3 $ 514.8 $ 550.4 Operating earnings as
Slide 16: Regulation G Schedules: Adjusted EBITDA Margin
Regulation G Schedules Adjusted EBITDA Margin Three Months Ended Three Months Ended Twelve Months Ended ($ Millions, except percentages) December 31, September 30, December 31, 2025 2024 2025 2025 2024 2023 Net earnings (loss) $ 19.7 $ 11.6 $ 13.7 $ 65.3 $ 55.5 $ 60.5 Net sales $ 137.3 $ 126.5 $ 143
Slide 17: Regulation G Schedules: Adjusted Net Earnings and Adjusted Diluted EPS
Regulation G Schedules Adjusted Net Earnings and Adjusted Diluted Earnings Per Share ($ Millions, except percentages and per share amounts) Three Months Ended Three Months Ended December 31, September 30, 2025 2025 2024 2024 2025 2025 Per share Per share Net earnings (A) $ 19.7 $ 0.67 $ 11.6 $ 0.38
Slide 18: Regulation G Schedules: Adjusted Net Earnings and Adjusted Diluted EPS
Regulation G Schedules Adjusted Net Earnings and Adjusted Diluted Earnings Per Share ($ Millions, except percentages and per share amounts) Twelve Months Ended December 31, 2025 2025 2024 2024 2023 2023 2022 2022 Per share Per share Per share Per share Net earnings (loss) (A) $ 65.3 $ 2.19 $ 55.5 $
Slide 19: Regulation G Schedules: Footnotes
Regulation G Schedules a) Reflected in Selling, general and administrative and other income (expense), net. b) Reflected in Cost of goods sold. c) Reflected in Restructuring charges. d) Reflected in Other income (expense), net. e) Reflected in Income tax expense. For 2023, discrete tax items include
Slide 20: Regulation G Schedules: Free Cash Flow
Regulation G Schedules Free Cash Flow ($ Millions, except percentages) Three Months Ended Twelve Months Ended December 31, December 31, 2025 2024 2025 2024 2023 Net cash provided by operating activities $ 29.2 $ 25.0 $ 102.1 $ 98.2 $ 88.8 Capital expenditures (3.2) (6.1) (15.7) (18.6) (14.7) Free ca